Hemoglobin based Protein Nanocarriers for Tumour Oxygenation and a more effective Photodynamic Therapy

Informations projet

OXIGENATED

N° de convention de subvention: 823879

DOI

10.3030/823879

Projet clôturé

Date de signature de la CE 18 Septembre 2018

Date de début 1 Mars 2019

Date de fin 31 Août 2024

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total

€ 920 000,00

Contribution de l’UE

€ 920 000,00

Coordonné par

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
Spain

Periodic Reporting for period 2 - OXIGENATED (Hemoglobin based Protein Nanocarriers for Tumour Oxygenation and a more effective Photodynamic Therapy)

Période du rapport: 2021-03-01 au 2024-08-31

Résumé du contexte et des objectifs généraux du projet

A major drawback of Photodynamic Therapy (PDT) and other therapies for cancer treatment is the limited oxygen content, hypoxia, in tumour tissue. In PDT a photosensitizing molecule is delivered to malignant tissue to generate radical oxygen species (ROS). The presence of oxygen is fundamental for ROS generation, ultimately causing the death of tumour cells. This project aims to develop hemoglobin drug delivery nanocarriers in the nano and submicron range for simultaneous oxygen and photosensitizer delivery to tumour tissue for a more efficient Photodynamic Therapy (PDT). A more efficient PDT can lead to a more effective treatment of certain cancers improving life expectation and quality of life of patients

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Hemoglobin-based nanocarriers (HOBCs) have been prepared by co-precipitation of hemoglobin with carbonates and surface coating with bovine serum albumin and alternatively through nanogel formation. It has been shown that transport oxygen complexed to hemoglobin while photosensitizer molecules have also been entrapped in the nanocarriers. Initial work has been performed in the modification of the carriers with homing peptides to target them to cancer cells. In vitro studies have also been started to study the uptake of HOBCs by cells, their intracellular fate, toxicity, and oxygen and photosensitizer delivery.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The OXIGENATED project has worked so far on the development of new nanoscale carriers for oxygen based on hemoglobin. The nanocarriers fabricated have potential applications on the treatment on cancer and can lead to more effective PDT therapies, which can have a positive impact on the life of patients, with a wide positive benefit for society. Moreover, OXIGENATED project has actively worked on exchanging skills and knowledge through secondments of Early Stage and Experienced Researchers, and through networking and training activities.

Logo OXIGENATED